Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
MOv18 IgE
DRUG
2 trials
Sponsors
Cancer Research UK
, Epsilogen Ltd
Conditions
Advanced Endometrial Cancer
Advanced Ovarian Cancer
Endometrial Cancer
Human Cancers
Platinum-resistant Ovarian Cancer
Triple -Negative Breast Cancer
Triple Negative Breast Cancer (TNBC)
Phase 1
Phase I Study of MOv18 IgE
Completed
NCT02546921
Cancer Research UK
Human Cancers
Start: 2016-02-16
End: 2021-07-30
Updated: 2023-06-05
A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
Recruiting
NCT06547840
Epsilogen Ltd
Advanced Endometrial Cancer, Advanced Ovarian Cancer, Endometrial Cancer +3
Start: 2024-09-03
End: 2027-03-01
Target: 45
Updated: 2026-04-06
Related Papers
A phase Ib, open-label trial of MOv18 IgE in patients with advanced ovarian cancer.
Journal of Clinical Oncology
2025-05-28
Non‐Allergic Urticarial Skin Reactions Associated With <scp>MOv18 IgE</scp>, a First‐In‐Class <scp>IgE</scp> Antibody Recognising Folate Receptor Alpha
Allergy
2025-03-06
3 citations
Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial.
2023-07-25
28 citations